User profiles for Mang M. Ma

Mang Ma

Other name: Mang M. Ma
Professor of Medicine, University of Alberta
Verified email at ualberta.ca
Cited by 7477

[PDF][PDF] Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value

P Tandon, M Ney, I Irwin, MM Ma… - Liver …, 2012 - Wiley Online Library
As detected by cross‐sectional imaging, severe muscle depletion, which is termed sarcopenia,
holds promise for prognostication in patients with cirrhosis. Our aims were to describe the …

Mutation in Hbv Rna–Dependent Dna Polymerase Confers Resistance to LamivudineIn Vivo

GA Tipples, MM Ma, KP Fischer, VG Bain… - Hepatology, 1996 - journals.lww.com
The (–) enantiomer of 3′–thiacytidine (lamivudine) has been found to be a potent inhibitor
of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) replication. Mutation of …

[PDF][PDF] Sirolimus‐based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma

…, M Al Saghier, GA Meeberg, M Blitz, MM Ma… - Liver …, 2004 - Wiley Online Library
An increasing number of patients with hepatocellular carcinoma (HCC) are undergoing
evaluation for listing for liver transplantation. Criteria for selection require ongoing review for …

Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease

…, MM Ma, M Mandorfer, M Mergeay-Fabre… - Official journal of the …, 2021 - journals.lww.com
METHODS: This is an international cohort study including patients with paired LSM/hepatic
venous pressure gradient (HVPG), LSM≥ 10 kPa, and no previous decompensation. Portal …

De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects

…, J Oberholzer, AMJ Shapiro, K Gutfreund, MM Ma… - …, 2007 - journals.lww.com
Background. We report long-term outcomes and side effects after transplantation for hepatocellular
carcinoma (HCC) using de novo, sirolimus-based immunosuppression (IS). Methods. …

Transplant immunosuppressive agents in non‐transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with …

N Chatur, A Ramji, VG Bain, MM Ma… - Liver …, 2005 - Wiley Online Library
Background: Conventional treatment of autoimmune hepatitis consists of either prednisone
alone or in combination with azathioprine. Ten to 20% of patients do not respond to or are …

Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines

CS Coffin, SK Fung, MM Ma - Canadian Journal of Gastroenterology …, 2012 - hindawi.com
Chronic hepatitis B (CHB) is a dynamic disease that is influenced by host and virological
factors. The management of CHB has become more complex with the increasing use of long-…

A shorter duration of pre-transplant abstinence predicts problem drinking after liver transplantation

P Tandon, KJ Goodman, MM Ma… - Official journal of the …, 2009 - journals.lww.com
OBJECTIVES: Liver transplantation for alcoholic liver disease (ALD) can be complicated by
abusive or “problem” drinking (PD) after transplant. There are limited data for evaluating the …

[PDF][PDF] Impact of implementing a “FIB‐4 first” strategy on a pathway for patients with NAFLD referred from primary care

…, M Al‐Karaghouli, JG Abraldes, MM Ma - Hepatology …, 2019 - Wiley Online Library
Detection of advanced fibrosis in nonalcoholic fatty liver disease (NAFLD) is essential for
stratifying patients according to the risk of liver‐related morbidity. Noninvasive methods such as …

Management of hepatitis B virus infection: 2018 guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and …

…, C Fournier, E Kelly, HH Ko, MM Ma… - Canadian Liver …, 2018 - canlivj.utpjournals.press
Hepatitis B virus (HBV) infection is an important public health problem in Canada. In keeping
with evolving evidence and understanding of HBV pathogenesis, the Canadian Association …